Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

It is interesting. I read the whole article.

The article proposes screening repurposed drugs for phospholipidoasis as a predictor of poor Covid 19 performance.

Since an antiviral has not been found to be effctive researchers could have screened for any biologic entity and would have come up with the same result.

Why is screening for phopholipidosis any different?

Is an obscure reference to phosphlipidosis pertinent to Brilacidin?

No, we are only days away from hearing the results of another group of patients being treated by Brilacidin. We do not need more in vitro testing when we are about to finish a clinical trial.

In Vitro testing for phospholipidosis has been available for decades.

Why doesn't the FDA mandate screening?.

GLTA,

Farrell